RCT 18

Drug Profile

RCT 18

Alternative Names: RC18; Tai’ai

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RC-Pharma
  • Developer RemeGen
  • Class Fibroblast cell therapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action B cell activating factor inhibitors; Tumour necrosis factor ligand superfamily member 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuromyelitis optica; Rheumatoid arthritis
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 21 Sep 2017 Phase-III clinical trials in Neuromyelitis optica in China (SC) (NCT03330418)
  • 01 Sep 2016 Phase-III clinical trials in Rheumatoid arthritis (Adjunctive treatment) in China (SC) (NCT03016013)
  • 30 Aug 2016 Phase-II clinical trials in Systemic lupus erythematosus in China (SC) (NCT02885610)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top